Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 12 | 2024 | 832 | 2.180 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2021 | 482 | 1.940 |
Why?
|
| T-Lymphocytes | 14 | 2024 | 1726 | 1.390 |
Why?
|
| Blood Platelets | 2 | 2024 | 327 | 1.280 |
Why?
|
| Oncolytic Virotherapy | 3 | 2020 | 85 | 0.900 |
Why?
|
| Cellular Senescence | 1 | 2024 | 161 | 0.800 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 701 | 0.760 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 84 | 0.730 |
Why?
|
| Genetic Vectors | 2 | 2021 | 940 | 0.690 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 543 | 0.690 |
Why?
|
| Neoplasms | 3 | 2022 | 2790 | 0.580 |
Why?
|
| Apoptosis | 1 | 2024 | 1806 | 0.550 |
Why?
|
| Genetic Therapy | 1 | 2020 | 687 | 0.510 |
Why?
|
| Genetic Engineering | 3 | 2019 | 159 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2024 | 889 | 0.420 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 177 | 0.380 |
Why?
|
| CD28 Antigens | 2 | 2024 | 81 | 0.380 |
Why?
|
| Antigens, Neoplasm | 3 | 2024 | 385 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 691 | 0.320 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 3348 | 0.290 |
Why?
|
| Mice | 11 | 2024 | 17633 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 536 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 772 | 0.270 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1242 | 0.240 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 557 | 0.230 |
Why?
|
| Animals | 13 | 2024 | 34235 | 0.230 |
Why?
|
| Adenoviridae | 2 | 2017 | 606 | 0.220 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2024 | 25 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 74 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 183 | 0.210 |
Why?
|
| Musa | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 164 | 0.200 |
Why?
|
| Dasatinib | 1 | 2022 | 40 | 0.200 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 3 | 0.200 |
Why?
|
| Transgenes | 2 | 2021 | 336 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 11 | 0.190 |
Why?
|
| Humans | 19 | 2024 | 125128 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 49 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2018 | 140 | 0.180 |
Why?
|
| Clinical Studies as Topic | 1 | 2020 | 9 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 154 | 0.180 |
Why?
|
| Cell Engineering | 1 | 2020 | 21 | 0.170 |
Why?
|
| Cell Survival | 2 | 2019 | 813 | 0.170 |
Why?
|
| Plasmids | 1 | 2021 | 513 | 0.170 |
Why?
|
| Cyclin A1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1203 | 0.170 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 20 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 294 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 73 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2020 | 93 | 0.160 |
Why?
|
| Leukemia | 1 | 2023 | 372 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2022 | 757 | 0.160 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 85 | 0.160 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 119 | 0.160 |
Why?
|
| Coculture Techniques | 1 | 2019 | 227 | 0.160 |
Why?
|
| Immunophenotyping | 1 | 2019 | 329 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 281 | 0.150 |
Why?
|
| Immunologic Memory | 1 | 2019 | 190 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 2513 | 0.140 |
Why?
|
| Gene Editing | 1 | 2019 | 187 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 684 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4395 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2020 | 590 | 0.130 |
Why?
|
| Cytokines | 2 | 2019 | 1289 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 461 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2019 | 2311 | 0.120 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 21 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 9 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 667 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 211 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 503 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 668 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1898 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1033 | 0.090 |
Why?
|
| Biomarkers | 1 | 2019 | 3091 | 0.090 |
Why?
|
| Adoptive Transfer | 2 | 2020 | 236 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12391 | 0.060 |
Why?
|
| Lectins | 1 | 2023 | 54 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1560 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 9 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 326 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2023 | 491 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 286 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 676 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1420 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 300 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 680 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2020 | 153 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1197 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 667 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 329 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 101 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2017 | 60 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 428 | 0.030 |
Why?
|
| Lymphocyte Transfusion | 1 | 2017 | 57 | 0.030 |
Why?
|
| A549 Cells | 1 | 2017 | 44 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 116 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 85 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 230 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 264 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 708 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2756 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 3056 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 515 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1506 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 470 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 569 | 0.030 |
Why?
|
| Female | 4 | 2021 | 66781 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 733 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 5845 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1894 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4534 | 0.020 |
Why?
|
| Male | 2 | 2020 | 61501 | 0.010 |
Why?
|